Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer

Cancer Science

Volumn 103, Issue 3, 2012, Pages 561-568

  Dong, Guanglong ^a   Guo, Xu ^b   Fu, Xiaoying ^c   Wan, Shaogui ^c   Zhou, Feng ^d   Myers, Ronald E ^c   Bao, Guoqiang ^d   Burkart, Ashlie ^c   Yang, Hushan ^c   Xing, Jinliang ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CHINESE; COLORECTAL CANCER; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; KDR GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ABDOMINAL SURGERY; ADJUVANT CHEMOTHERAPY; ASIAN; COLORECTAL TUMOR; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK FACTOR; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 84859729519     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02194.x     Document Type: Article

References (40)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Ferrari P, Jenab M, Norat T et al. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 2007; 121: 2065-72.
3. Pomerantz MM, Ahmadiyeh N, Jia L et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 2009; 41: 882-4.
4. Tuupanen S, Turunen M, Lehtonen R et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 2009; 41: 885-90.
5. Goel A, Boland CR. Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol 2010; 26: 47-52.
6. Chen J, Xie F, Chen K et al. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Cancer Biol Ther 2009; 8: 1424-30.
7. Xing J, Myers RE, He X et al. GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis. Eur J Cancer 2011; 47: 1699-707.
8. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003; 3: 912-20.
9. Castro FA, Forsti A, Buch S et al. TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer 2011; 47: 1203-10.
10. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
11. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Metastasis: lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2: 573-83.
12. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-49.
13. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21: 154-65.
14. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
15. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007; 62: 179-213.
16. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312: 549-60.
17. cSmith NR, Baker D, James NH et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010; 16: 3548-61.
18. Hansen TF, Sorensen FB, Spindler KL et al. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch 2010; 456: 251-60.
19. Loupakis F, Cremolini C, Fioravanti A et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011; 104: 1262-9.
20. Abulafi AM, Williams NS. Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg 1994; 81: 7-19.
21. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
22. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-88.
23. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-8.
24. Amaya H, Tanigawa N, Lu C et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 1997; 119: 227-35.
25. Duff SE, Jeziorska M, Rosa DD et al. Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer 2006; 42: 112-17.
26. Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 2008; 68: 285-91.
27. Wang Y, Zheng Y, Zhang W et al. Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 2007; 50: 760-7.
28. Zhang W, Sun K, Zhen Y et al. VEGF receptor-2 variants are associated with susceptibility to stroke and recurrence. Stroke 2009; 40: 2720-6.
29. Kim DH, Xu W, Kamel-Reid S et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol 2010; 21: 1179-88.
30. Sjostrom S, Wibom C, Andersson U et al. Genetic variations in VEGF and VEGFR2 and glioblastoma outcome. J Neurooncol 2010; 104: 523-7.
31. Beeghly-Fadiel A, Shu XO, Lu W et al. Genetic variation in VEGF family genes and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study. Cancer Epidemiol Biomarkers Prev 2011; 20: 33-41.
32. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26: 4672-8.
33. Steeghs N, Gelderblom H, Wessels J et al. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. Invest New Drugs 2011; 29: 137-43.
34. Pohl A, Lurje G, Manegold PC, Lenz HJ. Pharmacogenomics and -genetics in colorectal cancer. Adv Drug Deliv Rev 2009; 61: 375-80.
35. Gerger A, El-Khoueiry A, Zhang W et al. Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2011; 17: 5783-92.
36. Chen MH, Tzeng CH, Chen PM et al. VEGF -460T -> C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. Pharmacogenomics J 2011; 11: 227-36.
37. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
38. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
39. Hecht JR, Trarbach T, Hainsworth JD et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 2011; 29: 1997-2003.
40. Van Cutsem E, Bajetta E, Valle J et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 2011; 29: 2004-10.